ISORAY INC (ISR)
US46489V1044 - Common Stock
ISORAY INC
NYSEARCA:ISR (2/17/2023, 7:04:00 PM)
0.384
+0 (+0.03%)
Company Profile
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 66 full-time employees. The company went IPO on 2002-05-31. The firm is engaged in the advancement of treatment applications for cancers throughout the body. The company is a producer of Cesium-131 brachytherapy seeds. The firm has also developed a lead-212 generator to secure isotope supply for clinical trials and commercial operations. Its lead-212 generator utilizes the isotope lead-212 to deliver alpha radiation specifically to cancer cells via specialized targeting peptides. The firm is also engaged in the development of imaging diagnostics. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are under Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at various academic institutions.
Company Info
ISORAY INC
350 Hills Street, Suite 106
Richland WASHINGTON 99354
P: 15093751202.0
CEO: Lori A. Woods
Employees: 66
Website: https://isoray.com/
ISR News
The appointment advances Perspective Therapeutics’ journey to become a global leader in the manufacturing and distribution of therapeutic Cesium-131...
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and...
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a...
Fiscal Calendar Year Changes from June to December Year End...
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and...
a year ago - Isoray, Inc. and Viewpoint Molecular Targeting, Inc.Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology MedicineISR Twits
Here you can normally see the latest stock twits on ISR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
